Easy. Not so Easy. Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? 4/28/2012

Similar documents
Case Discussion. Disclosures. Critical Limb Ischemia: A Selective Approach to Revascularization Works Best 4/28/2012. None. 58 yo M, DM, CAD, HTN

4/23/2009. Vein Bypass Remains the Gold Standard AND We Can Improve Outcomes. Lower Extremity Revascularization Options: Key Factors to Consider

Endovascular Should Be Considered First Line Therapy

John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division

Disclosures. Objectives. Bypass vs. Endo for SFA Disease: Reaching Consensus on a Rational Approach. Christopher D. Owens, MD 4/23/2009

Surgical Options for revascularisation P E T E R S U B R A M A N I A M

Practical Point in Holistic Diabetic Foot Care 3 March 2016

LIMB SALVAGE IN THE DIABETIC PATIENT

Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization

Interventional Treatment First for CLI

Stratifying Management Options for Patients with Critical Limb Ischemia: When Should Open Surgery Be the Initial Option for CLI?

3-year results of the OLIVE registry:

Disclosures. Talking Points. An initial strategy of open bypass is better for some CLI patients, and we can define who they are

Lower Extremity Peripheral Arterial Disease: Its All About the Pulse. Spence M Taylor, M.D.

Surgery is and Remains the Gold Standard for Limb-Threatening Ischemia

Do the newest grafts achieve comparable results to saphenous vein bypass? THE HEPARIN-BONDED eptfe GRAFT. C. Pratesi

Disclosures. Tips and Tricks for Tibial Intervention. Tibial intervention overview

Lower Extremity Peripheral Arterial Disease: Less is Sometimes More. Spence M Taylor, M.D.

SAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS

Current Status of Endovascular Therapies for Critical Limb Ischemia

The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio

Isolated femoral endarterectomy: Impact of SFA TASC classification on recurrence of symptoms and need for additional intervention

National Vascular Registry

National Vascular Registry

Pedal Bypass With Deep Venous Arterialization:

Peripheral arterial disease for primary care Ed Aboian, MD

The Society for Vascular Surgery s. Objective Performance Goals for Lower Extremity Revascularization

SPINACH Making Limb Salvage Salad from Spinach alone

The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions

Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia

BEST-CLI Trial Study Concept and Current Status

Limb Salvage in Diabetic Ischemic Foot. Kritaya Kritayakirana, MD, FACS Assistant Professor Chulalongkorn University April 30, 2017

Lower Extremity Revascularization D oes Anesthesia Matter. Onaona Gurney PGY 4

Update on BEST-CLI Trial

Critical Limb Ischemia: Diagnosis and Current Management

Quality ID #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Angiosome revascularization strategies in real world practice: how much difference does it make?

Critical Limb Ischemia A Collaborative Approach to Patient Care. Christopher LeSar, MD Vascular Institute of Chattanooga July 28, 2017

GLOBAL VASCULAR GUIDELINES: A NEW PATHWAY FOR LIMB SALVAGE

Olive registry: 3-years outcome of BTK intervention in Japan. Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan

Popliteal Aneurysm: When is surgical therapy indicated? PROF. GRZEGORZ OSZKINIS

Access strategy for chronic total occlusions (CTOs) is crucial

Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis

Introduction to Peripheral Arterial Disease. Stacey Clegg, MD Interventional Cardiology August

Predicting ambulation status one year after lower extremity bypass

Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid?

Acknowledgements. No tengo conflictos de interés que revelar. I have no conflicts of interest to disclose. Michael S. Conte. David G.

Peripheral Arterial Disease: the growing role of endovascular management

Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -

Predictors of Postoperative Outcome in Patients with Lower Limb Surgical Revascularization

The influence of the characteristics of ischemic tissue lesions on ulcer healing time after infrainguinal bypass for critical leg ischemia

The effect of postoperative stroke and myocardial infarction on long-term survival after carotid revascularization

PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014

Disclosures. Critical Limb Ischemia. Vascular Testing in the CLI Patient. Vascular Testing in Critical Limb Ischemia UCSF Vascular Symposium

Distal By-Pass procedures can reduce limb loss

Practical Point in Diabetic Foot Care 3-4 July 2017

Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC

Francisco Acín, César Varela, Ignacio López de Maturana, Joaquín de Haro, Silvia Bleda, and Javier Rodriguez-Padilla

Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery

Peripheral Arterial Disease: Who has it and what to do about it?

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb

Arthroplasty after previous surgery: previous vascular problems

Distal hybrids - an option in long SFA CTO accompanied by severely compromized crural runoff

How Do We Optimize the Medical Therapy of Patients with Critical Limb Ischemia?

Imaging Strategy For Claudication

When and how to use distal protection devices for lower extremity revascularization. Peter A. Schneider, MD Kaiser Foundation Hospital, Honolulu

Global Vascular Guideline on the Management of Chronic Limb Threatening Ischemia -a new foundation for evidence-based care

LIBERTY 360 Study. 15-Jun-2018 Data 1. Olinic Dm, et al. Int Angiol. 2018;37:

Current Vascular and Endovascular Management in Diabetic Vasculopathy

Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria

Now That You Have the Tools

PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016

The Burden of CLI and Crosser Catheter Recanalization Strategies

Disclosure. I do not have any potential conflict of interest

OCT Guided Atherectomy: Initial Results of the VISION Trial Using the Pantheris Catheter. Patrick Muck, MD

Supplementary Appendix

Berman distal revascularization-interval

DON T LET LEG PAIN BECOME A REAL THREAT.

9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge

Steal Syndrome: The Role of the Vascular Lab

Social History. Retired internist 2 scotches a day 50 pack-year history, stopped in 2005

John E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division

Disclosures. In-Stent Restenosis: The Tail IS Wagging the Dog 4/15/2016. Restenosis: The Continuing Challenge for Peripheral Vascular Intervention

2-YEAR DATA SUPERA POPLITEAL REAL WORLD

Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events

Powerful patency. A decade of performance.

PUT YOUR BEST FOOT FORWARD

Infrainguinal bypass grafting in patients with endstage renal disease: Improving outcomes?

The Struggle to Manage Stroke, Aneurysm and PAD

Resident Teaching Conference 3/12/2010

Does heparin impregnated graft improve patency and reduce the cost of lower limb bypass? The REPLACE trial Y. Gouëffic, MD, PhD

A Case for Mandatory Routine Graft Surveillance of lower extremity bypass grafts. Avishai Meyer UCHSC resident, Surgery May 8, 2006

Supplementary Online Content

Multidisciplinary approach to BTK Y. Gouëffic, MD, PhD

Peripheral Artery Disease Interventions Utilizing the Angiosomal Approach to the Complex Wound

Treatment Strategies For Patients with Peripheral Artery Disease

11/20/2014. Disclosures. Kissing Balloons and Stents. Treatment of Aortoiliac Occlusive Disease. Data on Patency of Kissing Stents.

Transcription:

Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? Easy 89 yo Non-ambulatory Multiple failed interventions Forefoot and heel gangrene Andres Schanzer, MD University of Massachusetts Medical School UCSF Vascular Symposium 77 yo Dialysis dependent Tissue loss Not so Easy CABG 2 years prior Lives at home independently Contralateral GSV present 7.5 Months Postop Angiogram: Mild iliac/cfa disease, occluded SFA/Pop with reconstitution of anterior tibial runoff to the foot 1

Predicting Outcomes Risk Stratification CLI is associated with a high risk of cardiovascular events including major limb loss, myocardial infarction, stroke and death. Decision Making Alternative Treatment Strategies Open surgical bypass traditionally has been the gold standard method for revascularization. 1. Endovascular techniques 2. Primary amputation 3. Conservative management 2

Goal: To develop and validate a prognostic risk index for patients with CLI considered for bypass surgery Research Design and Methods Study Design Retrospective review of three prospectively collected databases to derive and then validate a risk prediction model Data Sources PREVENT III 14 CLI patients from 83 hospitals External validation cohort * 716 CLI patients from 3 hospitals (BWH, USF, Sarasota Memorial) VSGNE 1166 CLI patients from 11 hospitals Schanzer et al, JVS, 9. *Schanzer et al, JVS,. Schanzer et al, JVS, 11. PIII CLI Risk Score Development 1. PREVENT III cohort randomly divided into a derivation set and a validation set Two-Thirds: PIII Derivation Set 14 patients One-Third: PIII Validation Set 953 patients 451 patients PIII CLI Risk Score Development 1. Derivation Multivariable model converted to a standard integer score system 2. Validation Internal validation (PIII validation set, n=451) External validation (External multicenter cohort, n=716) External validation (VSGNE, n=1166) External validation (Finland, n=1425) 3

Results Multivariable Model for 1-Year AFS COVARIATES Dialysis CLI criterion Age 75 years Hematocrit < History of advanced CAD Integer score 4 3 2 2 1 PIII Derivation Set Stratified by Risk Score COVARIATES Dialysis CLI criterion Age 75 years Hematocrit < History of advanced CAD β HR coefficient (95% CI) 2.81 1.3 (1.97, 3.99) <.1 4 2.22.8 (1.43, 3.44).4 1.6.5 (1.21-2.22).1 1.61.48 (1.11, 2.34).12 1.41.34 (1.5, 1.88).21 Risk Score Amputation-Free Survival (%) Integer P-Value score 1 93.1 2 89.7 3 86.2 4 81.1 5 76.1 6 74.5 7 71.7 8 63 9 51 44 11 27.3 12 33 LOW MED HIGH Discrimination PIII Derivation Set Stratified by Risk Score Risk Categories Integer Score Amputation- Free Survival HR p-value Low 3 85.9 1. (ref) Medium 4-7 73. 2.11 (1.54-2.89) <.1 High 8 44.6 5.5 (3.73-8.) <.1 PREVENT III DERIVATION SET N=953 9 8 7 6 5 PIII RISK SCORE for CRITICAL LIMB ISCHEMIA POINTS DIALYSIS 4 TISSUE LOSS 3 AGE 75 2 HCT % 2 CAD 1 9 8 7 6 5 4

Internal Validation 8 7 6 5 PREVENT III DERIVATION SET N=953 9 PREVENT III VALIDATION SET N=451 9 8 7 6 5 88% 64% <4 Points 4-8 Points >8 Points External Validation 1 PREVENT III DERIVATION SET N=953 9 8 7 6 5 9 8 7 6 5 BWH/USF/FSU DATASET N=716 7% 48% External Validation 2 PREVENT III DERIVATION SET N=953 9 8 7 6 5 9 8 7 6 5 VSGNNE DATASET N=1166 74% 56% <4 Points 4-8 Points >8 Points Characteristics DEMOGRAPHICS Age 75 African American MEDICATIONS Statin Beta-blocker RISK FACTORS Previous ipsilateral bypass Smoking (ever) Hypertension High cholesterol Ankle brachial index <.3 * Weight >75 kg SURGICAL CHARACTERISTICS Proximal anastomosis site CFA Distal anastomosis site Popliteal Single segment GSV conduit PIII Derivation Set n=953 (%) 7 (32.2) 173 (18.2) 431 (45.2) 554 (58.1) 138 (14.5) 79 (74.6) 774 (81.2) 445 (46.7) 457 (73.2) 52 (53.5) 464 (48.7) 3 (34.5) 781 (82.) VSGNNE Validation Set n=1166 (%) 443 (38.) 8 (.7) 386 (66.3) 494 (84.7) 124 (.6) 923 (79.4) 22 (87.7) 632 (54.3) 182 (24.1) 4 (37.7) 78 (6.7) 483 (41.2) 993 (85.3) p-value.6 <.1 <.1 <.1.7.9 <.1.5 <.1 <.1 <.1.1.42 5

Results-Validation Results-Validation Amputation-Free Survival AFS at One Year by Risk Category 9 85.9 87.7 86.3 86.4 8 73 63.7 7.1 74.1 7 6 56.1 5 44.6 45. 47.8 Low ( 3) Medium (4-7) High ( 8) PIII Derivation Set (n=953) Risk category (integer PIII Validation score) Set (n=451) Retrospective Validation Set (n=716) VSGNNE VALIDATION SET (n=1166) JVS, November, Conclusions The PIII Risk Score is easily used at initial presentation using five simple dichotomous variables: Dialysis-Dependency Tissue Loss on Presentation Hematocrit % Age 75 History of Advanced CAD Conclusions The PIII Risk Score is GENERALIZABLE Dialysis-Dependency Tissue Loss on Presentation Hematocrit % Age 75 History of Advanced CAD 6

The PIII risk score is a useful clinical tool for treatment decision planning Does it allow us to answer the question: Who is Likely to Benefit from Revascularization and Who is Not? PIII RISK SCORE for CRITICAL LIMB ISCHEMIA POINTS DIALYSIS 4 TISSUE LOSS 3 AGE 75 2 HCT % 2 CAD 1 9 8 7 6 5 VSGNE LEB Risk Prediction Models Amputation or graft occlusion at 1 year * Death at 1 year Ambulation status at 1 year Clinical failure, despite graft patency, at 1 year *Goodney et al, Annals of Vasc Surg,. Goodney et al, JVS, 9. Goodney et al, JVS,. Simons et al, JVS,. 7

Patients with no risk factors had amputation rates <1%; patients with >3 risk factors had nearly % chance of suffering amputation. Patients with no risk factors had 1-year death rates <5%; patients with >3 risk factors had 28% chance of dying by 1 year. *Goodney et al, Annals of Vasc Surg,. Goodney et al, JVS,. Likelihood of nonambulatory status at 1 year was <5% in patients with no risk factors and nearly 5% in patients with >3. After lower extremity bypass for CLI, % of patients with a patent graft did not achieve clinical improvement at 1 year. Goodney et al, JVS, 9. Simons et al, JVS,. 8

9

Risk Assessment in the CLI Patient: Who is Likely to Benefit from Revascularization and Who is Not? We lack validated instruments to accurately answer this question We can predict some specific outcomes at specific time points with relatively reliable accuracy (i.e. <5% likelihood that patient is alive with an intact limb) The best we can do is try to use available data to help inform patient and physician decision-making

Thank You. 11